NTRK1 and neoplasm: Concurrently, the tumor activates the phosphoinositide 3-kinase (PI3K) and receptor tyrosine kinase–RAS (RTK–RAS) signaling pathways, resulting in unchecked cell proliferation and suppression of anti-tumor immune responses (8).